Comprehensive transcriptomic profiling identifies breast cancer patients who may be spared adjuvant systemic therapy
(2020) In Clinical Cancer Research 26(1). p.171-182- Abstract
Purpose: There is currently no molecular signature in clinical use for adjuvant endocrine therapy omission in breast cancer. Given the unique trial design of SweBCG91-RT, where adjuvant endocrine and chemotherapy were largely unadministered, we sought to evaluate the potential of transcriptomic profiling for identifying patients who may be spared adjuvant endocrine therapy. Experimental Design: We performed a whole-transcriptome analysis of SweBCG91-RT, a randomized phase III trial of ± radiotherapy after breast-conserving surgery for node-negative stage I–IIA breast cancer. Ninety-two percent of patients were untreated by both adjuvant endocrine therapy and chemotherapy. We calculated 15 transcriptomic signatures from the literature... (More)
Purpose: There is currently no molecular signature in clinical use for adjuvant endocrine therapy omission in breast cancer. Given the unique trial design of SweBCG91-RT, where adjuvant endocrine and chemotherapy were largely unadministered, we sought to evaluate the potential of transcriptomic profiling for identifying patients who may be spared adjuvant endocrine therapy. Experimental Design: We performed a whole-transcriptome analysis of SweBCG91-RT, a randomized phase III trial of ± radiotherapy after breast-conserving surgery for node-negative stage I–IIA breast cancer. Ninety-two percent of patients were untreated by both adjuvant endocrine therapy and chemotherapy. We calculated 15 transcriptomic signatures from the literature and combined them into an average genomic risk, which was further used to derive a novel 141-gene signature (MET141). All signatures were then independently examined in SweBCG91-RT and in the publicly available METABRIC cohort. Results: In SweBCG91-RT, 454 patients were node-negative, postmenopausal, and systemically untreated with ER-positive, HER2-negative cancers, which constitutes a low-risk subgroup and potential candidates for therapy omission. Most transcriptomic signatures were highly prognostic for distant metastasis, but considerable discordance was observed on the individual patient level. Within the MET141 low-risk subgroup (lowest 25th percentile of scores), 95% of patients were free of metastasis at 15 years, even in the absence of adjuvant endocrine therapy. In a clinically low-risk subgroup of the METABRIC cohort not treated with systemic therapy, no breast cancer death occurred among the MET141 low-risk patients. Conclusions: Transcriptomic profiling identifies patients with an excellent outcome without any systemic adjuvant therapy in clinically low-risk patients of the SweBCG91-RT and METABRIC cohorts.
(Less)
- author
- organization
- publishing date
- 2020-01
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Clinical Cancer Research
- volume
- 26
- issue
- 1
- pages
- 12 pages
- publisher
- American Association for Cancer Research
- external identifiers
-
- scopus:85077477468
- pmid:31558478
- ISSN
- 1078-0432
- DOI
- 10.1158/1078-0432.CCR-19-1038
- language
- English
- LU publication?
- yes
- id
- 7bd9c597-d500-4fd6-8180-6b769f87d006
- date added to LUP
- 2020-01-21 15:48:03
- date last changed
- 2024-06-13 10:04:51
@article{7bd9c597-d500-4fd6-8180-6b769f87d006,
abstract = {{<p>Purpose: There is currently no molecular signature in clinical use for adjuvant endocrine therapy omission in breast cancer. Given the unique trial design of SweBCG91-RT, where adjuvant endocrine and chemotherapy were largely unadministered, we sought to evaluate the potential of transcriptomic profiling for identifying patients who may be spared adjuvant endocrine therapy. Experimental Design: We performed a whole-transcriptome analysis of SweBCG91-RT, a randomized phase III trial of ± radiotherapy after breast-conserving surgery for node-negative stage I–IIA breast cancer. Ninety-two percent of patients were untreated by both adjuvant endocrine therapy and chemotherapy. We calculated 15 transcriptomic signatures from the literature and combined them into an average genomic risk, which was further used to derive a novel 141-gene signature (MET141). All signatures were then independently examined in SweBCG91-RT and in the publicly available METABRIC cohort. Results: In SweBCG91-RT, 454 patients were node-negative, postmenopausal, and systemically untreated with ER-positive, HER2-negative cancers, which constitutes a low-risk subgroup and potential candidates for therapy omission. Most transcriptomic signatures were highly prognostic for distant metastasis, but considerable discordance was observed on the individual patient level. Within the MET141 low-risk subgroup (lowest 25th percentile of scores), 95% of patients were free of metastasis at 15 years, even in the absence of adjuvant endocrine therapy. In a clinically low-risk subgroup of the METABRIC cohort not treated with systemic therapy, no breast cancer death occurred among the MET141 low-risk patients. Conclusions: Transcriptomic profiling identifies patients with an excellent outcome without any systemic adjuvant therapy in clinically low-risk patients of the SweBCG91-RT and METABRIC cohorts.</p>}},
author = {{Sjöström, Martin and Laura Chang, S. and Fishbane, Nick and Davicioni, Elai and Hartman, Linda and Holmberg, Erik and Feng, Felix Y. and Speers, Corey W. and Pierce, Lori J. and Malmström, Per and Fernö, Mårten and Karlsson, Per}},
issn = {{1078-0432}},
language = {{eng}},
number = {{1}},
pages = {{171--182}},
publisher = {{American Association for Cancer Research}},
series = {{Clinical Cancer Research}},
title = {{Comprehensive transcriptomic profiling identifies breast cancer patients who may be spared adjuvant systemic therapy}},
url = {{http://dx.doi.org/10.1158/1078-0432.CCR-19-1038}},
doi = {{10.1158/1078-0432.CCR-19-1038}},
volume = {{26}},
year = {{2020}},
}